Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression

Kim, Minhee; Lee, Jong Sam; Kim, Woo-Yeon; Lee, Jong-Hun; Jun, Bong‐Hyun; Kim, Keun-Sik; Kim, Dong-Eun

doi:10.1016/j.jconrel.2022.06.039

Cited by 79 publications

(44 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanocarriers, including liposomes, can be transported into the cells through several energy-dependent endocytosis mechanisms, by which the nanocarriers are sequestered in endocytic vesicles. 46 A detailed understanding of the uptake mechanism of SA-modified cationic liposomes by TAMs would contribute to developing better antitumor drug delivery systems. We investigated the cellular uptake mechanism of cationic liposomes in RAW264.7 cells using various endocytosis inhibitors: chlorpromazine, filipin III, and amiloride, which were widely used to block clathrin-mediated endocytosis, caveolae-mediated endocytosis, and micropinocytosis, respectively.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors

Sun

Sui

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Mechanism Of Cationic Liposomes Endocytosismentioning

confidence: 99%

A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors

Sun

Sui

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…For example, the concomitant administration of cisplatin [ 40 ] and siPD-L1 [ 72 ] by the PLGA polymeric nanoparticles, which we equipped with TNBC aptamers, may not only promote a reduction in toxic side effects but also counteract the reported negative effect of cisplatin administration on the enrichment of PD-L1+ immune evasive TNBC cells [ 73 ]. In this regard, Kim et al prepared a multifunctional nanosystem having two DNA aptamers conjugated on the external surface of liposomes and two different therapeutics inside nanovectors for synergistic chemoimmunotherapy in TNBC [ 74 ]. Specifically, they used, for TNBC cells targeting, the previously selected anti-CD44 [ 75 ] and anti-PD-L1 [ 76 ] DNA aptamers, each thiol-modified and covalently conjugated to maleimide groups of PEGylated-DSPE micelles by thiol–maleimide chemistry.…”

Section: Aptamer-based Immune Strategies For Tnbc Treatmentmentioning

confidence: 99%

Aptamer-Based Strategies to Boost Immunotherapy in TNBC

Agnello

d’Argenio

Nilo

et al. 2023

Cancers

View full text Add to dashboard Cite

The immune system (IS) may play a crucial role in preventing tumor development and progression, leading, over the last years, to the development of effective cancer immunotherapies. Nevertheless, immune evasion, the capability of tumors to circumvent destructive host immunity, remains one of the main obstacles to overcome for maximizing treatment success. In this context, promising strategies aimed at reshaping the tumor immune microenvironment and promoting antitumor immunity are rapidly emerging. Triple-negative breast cancer (TNBC), an aggressive breast cancer subtype with poor outcomes, is highly immunogenic, suggesting immunotherapy is a viable strategy. As evidence of this, already, two immunotherapies have recently become the standard of care for patients with PD-L1 expressing tumors, which, however, represent a low percentage of patients, making more active immunotherapeutic approaches necessary. Aptamers are short, highly structured, single-stranded oligonucleotides that bind to their protein targets at high affinity and specificity. They are used for therapeutic purposes in the same way as monoclonal antibodies; thus, various aptamer-based strategies are being actively explored to stimulate the IS’s response against cancer cells. The aim of this review is to discuss the potential of the recently reported aptamer-based approaches to boost the IS to fight TNBC.

show abstract

“…The CD44-anti-PD-L1 aptamer has been used in a targeted drug delivery system using nanosized liposomes. These liposomes have been loaded with loaded DOX and IDO1 siRNA and conjugated to CD44 and anti-PD-L1 DNA aptamers that target breast cancer cells and inhibit the PD-1/PD-L1 interaction between cancer cells and T cells [ 93 ]. An anti-EGFR-CD44 aptamer was used to target doxorubicin loaded in solid lipid nanoparticles to triple-negative breast cancer cells in which the receptor is overexpressed.…”

Section: Dna-based Materialsmentioning

confidence: 99%

DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors

Shishparenok

Furman

Zhdanov

2023

Cancers

View full text Add to dashboard Cite

DNA nanotechnology has significantly advanced and might be used in biomedical applications, drug delivery, and cancer treatment during the past few decades. DNA nanomaterials are widely used in biomedical research involving biosensing, bioimaging, and drug delivery since they are remarkably addressable and biocompatible. Gradually, modified nucleic acids have begun to be employed to construct multifunctional DNA nanostructures with a variety of architectural designs. Aptamers are single-stranded nucleic acids (both DNAs and RNAs) capable of self-pairing to acquire secondary structure and of specifically binding with the target. Diagnosis and tumor therapy are prospective fields in which aptamers can be applied. Many DNA nanomaterials with three-dimensional structures have been studied as drug delivery systems for different anticancer medications or gene therapy agents. Different chemical alterations can be employed to construct a wide range of modified DNA nanostructures. Chemically altered DNA-based nanomaterials are useful for drug delivery because of their improved stability and inclusion of functional groups. In this work, the most common oligonucleotide nanomaterials were reviewed as modern drug delivery systems in tumor cells.

show abstract

Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression

Cited by 79 publications

References 53 publications

A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors

A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors

Aptamer-Based Strategies to Boost Immunotherapy in TNBC

DNA-Based Nanomaterials as Drug Delivery Platforms for Increasing the Effect of Drugs in Tumors

Contact Info

Product

Resources

About